Urolithin A (UroA) is a metabolite produced by gut bacteria when they break down dietary ellagitannins, compounds found in foods such as pomegranates, berries, and walnuts. Over the past decade, researchers have uncovered that UroA can stimulate a specific cellular recycling pathway called mitophagy, which removes damaged mitochondria and promotes the formation of healthy ones.
Because mitochondria are the power plants of cells, their quality control is crucial for tissues that rely heavily on energy, such as muscle and brain. A growing body of pre‑clinical and early‑clinical work shows that UroA‑induced mitophagy improves mitochondrial function, muscle performance, and even cognitive outcomes in disease models. This article summarizes the mechanistic evidence and the key human studies, while highlighting the current limits of the data.
Key Takeaways
- Urolithin A is a gut‑derived metabolite that reliably activates mitophagy across worms, rodents, and humans.
- The primary molecular route involves TFEB activation, which amplifies the PINK1/Parkin mitophagy pathway and improves lysosomal function.
- Human trials show that short‑term UroA supplementation is safe and can improve muscle performance and mitochondrial biomarkers, but long‑term clinical outcomes remain unproven.
- Benefits have been observed in models of muscle aging, muscular dystrophy, and Alzheimer’s disease, suggesting relevance for age‑related functional decline.
- Evidence is still emerging; UroA should be viewed as a nutritional supplement, not a therapeutic cure.
What Is Mitophagy and Why Does It Matter?
Mitophagy is a selective form of autophagy that targets dysfunctional mitochondria for degradation in lysosomes. The process involves recognition of damaged mitochondria, recruitment of the autophagy machinery, and delivery to lysosomes where the organelle is broken down and its components are recycled. Efficient mitophagy prevents the accumulation of reactive oxygen species, maintains ATP production, and supports cellular longevity.
Impaired mitophagy has been linked to age‑related decline in muscle strength, neurodegeneration, and metabolic disorders. Restoring this pathway is therefore a logical target for interventions aimed at healthy aging.
Urolithin A Triggers Mitophagy in Model Organisms
The first clear demonstration that UroA can activate mitophagy came from studies in the nematode Caenorhabditis elegans, where dietary supplementation prolonged lifespan and improved mitochondrial health markers [1]. In the same paper, rodents given UroA showed enhanced muscle function that correlated with increased expression of mitophagy genes (PINK1, Parkin) and reduced accumulation of damaged mitochondria.
Follow‑up work in mouse models of muscular dystrophy confirmed that UroA‑induced mitophagy restored muscle contractility and reduced fibrosis, effects that were lost when the transcription factor TFEB—a master regulator of lysosomal biogenesis—was genetically blocked [3]. These animal data collectively illustrate that UroA acts upstream of the TFEB‑PINK1/Parkin axis to promote the clearance of defective mitochondria.
Human Evidence: Safety and Molecular Signatures
A randomized, double‑blind trial in healthy middle‑aged adults demonstrated that 12 weeks of UroA supplementation was safe and produced a reproducible molecular signature of improved mitochondrial and cellular health. Blood biomarkers showed increased circulating levels of mitochondrial DNA fragments indicative of turnover, and muscle biopsies revealed up‑regulation of mitophagy‑related genes [2].
The same group later reported functional outcomes: participants experienced modest gains in hand‑grip strength, walking speed, and exercise performance, alongside higher plasma levels of the mitophagy marker PINK1 [5]. A systematic review of human trials concluded that, while the data are still limited, UroA consistently activates pathways linked to mitochondrial quality control without serious adverse events [8].
Mechanistic Pathways: TFEB, PINK1/Parkin, and Lysosomal Renewal
Mechanistic studies converge on three interrelated nodes. First, UroA stabilizes the transcription factor TFEB, which translocates to the nucleus and drives expression of genes involved in lysosomal biogenesis and autophagy [4]. Second, TFEB activation enhances the PINK1/Parkin cascade, the canonical route by which damaged mitochondria are tagged for degradation. Third, UroA improves lysosomal acidification, ensuring that engulfed mitochondria are efficiently broken down [7].
In a mouse model of Alzheimer’s disease, oral UroA restored both mitophagy and lysosomal function, leading to reduced amyloid‑β accumulation and improved spatial memory, providing a proof‑of‑concept that coordinated activation of these pathways can translate into functional brain benefits [7].
Potential Clinical Implications and Ongoing Research
The strongest translational signals are in muscle aging and neurodegeneration. In older adults, UroA‑driven mitophagy may help maintain muscle power, a key predictor of independence. In the brain, restoring mitochondrial quality could attenuate the bioenergetic deficits that precede cognitive decline.
Current research is expanding to cancer biology, where UroA was shown to activate TFEB‑mediated mitophagy in tumor‑associated macrophages and slow breast cancer progression in mice [6]. Although these findings are early, they illustrate the breadth of conditions in which mitophagy modulation might be relevant.
Where to Find Urolithin A
- Urolithin A supplements on Amazon (generic, budget-friendly)
- Mitopure by Timeline (the clinically studied branded form)
As an Amazon Associate we earn from qualifying purchases.
A Note on the Evidence
Evidence is still limited to short‑term studies in healthy or disease‑model subjects; people with medical conditions should discuss use with a doctor before starting supplementation.
Frequently Asked Questions
How does urolithin A differ from other antioxidants?
Unlike broad‑spectrum antioxidants, UroA specifically triggers the cellular recycling of damaged mitochondria rather than merely scavenging free radicals. This targeted effect is mediated through TFEB and the PINK1/Parkin pathway [4].
Can I take urolithin A to prevent Alzheimer’s disease?
Animal studies show that UroA restores mitophagy and improves cognition in Alzheimer’s models, but human evidence is limited to safety and biomarker changes. It should not be considered a preventive treatment without medical guidance [7].
What dosage was used in the human trials?
The randomized trial in middle‑aged adults used 500 mg of purified UroA per day for 12 weeks, which was well tolerated and produced measurable molecular effects [2].
Is urolithin A effective for everyone?
Efficacy appears to depend on the presence of gut bacteria that can convert ellagitannins to UroA, as well as individual mitochondrial health status. People with severe liver or kidney disease were not included in trials, so safety in those groups is not established.
How long does it take to see an effect?
In the human muscle study, improvements in strength and mitochondrial markers were detectable after 8–12 weeks of daily supplementation [5].
Does urolithin A interact with medications?
No drug‑interaction studies have been published yet. Individuals taking prescription medications should consult a healthcare professional before adding UroA supplements.
References
- Ryu D et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature medicine (2016). PMID 27400265
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Luan P et al. Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy. Science translational medicine (2021). PMID 33827972
- D'Amico D et al. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends in molecular medicine (2021). PMID 34030963
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Zheng B et al. Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages. Journal of advanced research (2025). PMID 38615740
- Hou Y et al. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimer's & dementia : the journal of the Alzheimer's Association (2024). PMID 38753870
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
